Top Page
Fusion Antibodies Plc
(LSE:FAB)
Fusion Antibodies Plc (FAB) vs. iShares MSCI United Kingdom ETF (EWC)
Fusion Antibodies Plc Business Overview & Revenue Model
Fusion Antibodies Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60M | 1.97M | 1.14M | 2.90M | 4.80M | 4.17M |
| Gross Profit | 290.00K | 430.00K | -265.00K | 202.00K | 1.72M | 1.31M |
| EBITDA | -1.36M | -1.62M | -2.06M | -2.48M | -573.00K | -532.00K |
| Net Income | -1.47M | -1.71M | -2.23M | -2.60M | -1.20M | -2.90M |
Balance Sheet | ||||||
| Total Assets | 1.81M | 1.32M | 2.42M | 2.06M | 4.92M | 5.83M |
| Cash, Cash Equivalents and Short-Term Investments | 252.00K | 359.00K | 1.20M | 195.00K | 2.05M | 2.69M |
| Total Debt | 388.00K | 20.00K | 43.00K | 75.00K | 69.00K | 230.00K |
| Total Liabilities | 1.09M | 654.00K | 627.00K | 939.00K | 1.23M | 1.08M |
| Stockholders Equity | 726.00K | 669.00K | 1.79M | 1.12M | 3.68M | 4.75M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -1.37M | -1.77M | -1.87M | -591.00K | -1.52M |
| Operating Cash Flow | -1.19M | -1.36M | -1.77M | -1.75M | -333.00K | -1.15M |
| Investing Cash Flow | -69.00K | -5.00K | 1.00K | -114.00K | -258.00K | -365.00K |
| Financing Cash Flow | 1.07M | 529.00K | 2.77M | 7.00K | -46.00K | 2.67M |
Fusion Antibodies Plc Technical Analysis
Fusion Antibodies Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £20.03M | ― | -164.37% | ― | -11.43% | 23.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £10.43M | -4.83 | -15.57% | ― | 13.32% | 55.07% | |
46 Neutral | £22.25M | -5.89 | -213.66% | ― | 39.88% | 81.33% | |
41 Neutral | £898.44K | -0.17 | ― | ― | 418.49% | 27.86% | |
40 Underperform | £6.26M | -0.11 | -333.59% | ― | 45.22% | 55.71% |
Fusion Antibodies Plc Corporate Events
Fusion Antibodies plc reported a reduction in losses and increased R&D expenditure in its interim results for the first half of FY2026, despite a decrease in revenue compared to the previous year. The company highlighted significant progress with its OptiMAL® platform, including a successful validation project with the National Cancer Institute and the granting of a US patent. The commercial launch of OptiMAL® is on track, with positive feedback from prospective clients, indicating potential for a scalable licensing-based business model. Fusion Antibodies is well-positioned to capitalize on a recovering market and aims to expand its offerings to include additional libraries for diagnostics and veterinary medicine.
Fusion Antibodies plc announced it will release its unaudited interim results for the six months ended 30 September 2025 on 24 November 2025. The company will host an online live presentation for investors on 25 November 2025, providing an opportunity for stakeholders to engage with the management team and receive updates on the company’s business and current trading. This announcement underscores Fusion’s commitment to transparency and investor engagement, potentially impacting its market positioning and stakeholder relations positively.
Fusion Antibodies plc has released a video featuring Dr. Richard Buick, CSO, discussing the science and technology behind their OptiMAL® library, which is set to launch commercially in December 2025. The OptiMAL® library, protected by a US patent, is designed to discover novel human antibodies and is part of the company’s strategy to provide innovative platforms that accelerate drug development, potentially enhancing their market position and offering significant benefits to stakeholders in the pharmaceutical and diagnostic industries.
Fusion Antibodies plc announced the successful validation of its OptiMAL® platform for isolating specific antibodies against both protein and peptide targets, marking a significant milestone in its collaboration with the National Cancer Institute. This development positions the company for the commercial launch of OptiMAL® in December 2025 and expands its market potential by enabling the use of the platform for a wider range of targets. The NCI has expressed interest in extending its agreement with Fusion, highlighting the platform’s potential as a leading tool in therapeutic antibody discovery.
Fusion Antibodies plc announced that all resolutions were passed at its recent annual general meeting. This development underscores the company’s stable governance and continued focus on advancing its strategic goals in the rapidly growing monoclonal antibody therapeutics market, which is projected to surpass $445 billion by 2028.
Fusion Antibodies plc reported a decrease in unaudited revenues for the first half of the financial year 2026 compared to the previous year, but an increase from the second half of 2025, with improved gross margins reflecting operational efficiency. The company achieved a significant milestone with a US patent for its OptiMAL® library design and continued its collaboration with the National Cancer Institute, which plans to use the platform for future projects. Fusion secured new contracts, including a stable cell line development for a US biotechnology company and multiple humanization projects, strengthening its industry position. The company anticipates a stronger performance in the second half of the year, supported by a robust order book and promising sales opportunities, and is on track with strategic goals, including the launch of OptiMAL® in December.
Fusion Antibodies plc has secured a new multi-target Integrated Therapeutic Antibody Services project with a European-based global pharmaceutical company. This project, which involves humanizing VHH antibody fragments, underscores Fusion’s strategic focus on partnering with major pharmaceutical firms to drive sustainable growth and enhance market positioning. The project is expected to be completed within the current financial year, generating revenues of at least £175,000, and highlights Fusion’s capability to deliver high-quality, innovative solutions.
Fusion Antibodies plc announced the posting of its Annual Report and Accounts for the year ended 31 March 2025, along with the Notice of its Annual General Meeting (AGM) scheduled for 16 October 2025. The company continues to focus on enhancing its industry positioning by leveraging technological advances to expedite drug development, which could have significant implications for stakeholders by potentially speeding up the delivery of new therapeutic and diagnostic solutions.
Fusion Antibodies plc has announced significant progress in its OptiMAL® project, a collaboration with the National Cancer Institute (NCI) to develop antibodies for cancer therapy and diagnostics. The NCI has expressed interest in extending the use of the OptiMAL® platform, which has successfully identified antibodies with commercially viable binding affinities. This development enhances Fusion’s industry positioning as a leader in pre-clinical antibody discovery and may have positive implications for stakeholders by potentially accelerating therapeutic and diagnostic projects targeting various cancers.
Fusion Antibodies plc announced an upcoming in-person investor presentation in Belfast on September 18, 2025. This event is part of the company’s strategy to engage with investors and showcase its advancements in antibody engineering services. The presentation reflects Fusion’s commitment to leveraging cutting-edge science to enhance its market position and support the global healthcare industry by expediting the drug development process.